| Literature DB >> 28826534 |
Allyn C Howlett1, Mary E Abood2.
Abstract
The CB1 and CB2 cannabinoid receptors (CB1R, CB2R) are members of the G protein-coupled receptor (GPCR) family that were identified over 20 years ago. CB1Rs and CB2Rs mediate the effects of Δ9-tetrahydrocannabinol (Δ9-THC), the principal psychoactive constituent of marijuana, and subsequently identified endogenous cannabinoids (endocannabinoids) anandamide and 2-arachidonoyl glycerol. CB1Rs and CB2Rs have both similarities and differences in their pharmacology. Both receptors recognize multiple classes of agonist and antagonist compounds and produce an array of distinct downstream effects. Natural polymorphisms and alternative splice variants may also contribute to their pharmacological diversity. As our knowledge of the distinct differences grows, we may be able to target select receptor conformations and their corresponding pharmacological responses. This chapter will discuss their pharmacological characterization, distribution, phylogeny, and signaling pathways. In addition, the effects of extended agonist exposure and how that affects signaling and expression patterns of the receptors are considered.Entities:
Keywords: Biased agonism; Cannabinoid; G protein; GPCR; Human; Polymorphism; Rodent; Splice variant; Tissue selectivity
Mesh:
Substances:
Year: 2017 PMID: 28826534 PMCID: PMC5812699 DOI: 10.1016/bs.apha.2017.03.007
Source DB: PubMed Journal: Adv Pharmacol ISSN: 1054-3589